10599 results for 'lcb antibodi'

Research Pulse · Data study Where biology is heading: what PubMed and 300,000 researcher visits reveal We compared five years of PubMed publication counts with two years of researcher visits to Assa

Low-dose IL-2 expands regulatory T cells. High-dose IL-2 expands the cells they exist to restrain. Same cytokine, same receptor family, opposite clinical intent — and the explanation is a receptor su

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target

Cancer Biology · GeneticsTumour Suppressor Genes: Roles, Examples & CancerTumour suppressor genes are the brakes on cell growth — they restrain proliferation, repair damaged DNA and trigger apoptosis

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel

QUICK ANSWER If your ELISA returns sample concentrations that are orders of magnitude too high, the assay itself is usually fine — the error is almost always in data analysis. The most

Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t

What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C

What is Parkinson’s disease? Parkinson's disease can be seen as a neurodegenerative disease because it is associated with the loss of nerve cel

CAR T-cell therapy CAR (Chimeric Antigen Receptor) T-cell Therapy is a type of cancer treatment. CAR T-cells are made in the laboratory and they have an artificially created receptor on the

What is VEGF? Vascular Endothelial Growth Factors (VEGFs) are a group of homodimeric polypeptides, and are master regulators of vascular development, maintenance and a

Harnessing Immune-Checkpoint Inhibition for Cancer Prevention Immune-checkpoint inhibition (ICI) has emerged as a pivotal strategy in cancer therapy, particularly in the context of tu